Vishnu Priya Murali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vishnu Priya Murali has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Rangasamy Jayakumar
School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, India
3 shared publications - Jessica Amber Jennings
Department of Biomedical Engineering, University of Memphis
2 shared publications A R Boccaccini
Institute of Biomaterials, University of Erlangen-Nuremberg, 91058 Erlangen, Germany
1 shared publicationA Sivshanmugam
Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham University, Kochi, 682041, India
1 shared publicationA. Sivashanmugam
1 shared publication- Amirthalingam Sivashanmugam
Center for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi 682041, India
1 shared publication
Latest Publications
- 8 April 2021
- Published by Wiley in Journal of Periodontal Research
- Vol. 56 (5) , 877-884
Simvastatin loaded chitosan guided bone regeneration membranes stimulate bone healing
Background and Objective: Electrospun chitosan membranes (ESCM) modified with short‐chain fatty acids have the ability to control the release of simvastatin (SMV), an anti‐cholesterol drug with osteogenic potential, for guided bone regeneration (GBR) applications. This study evaluated in vivo osteogenic effects of rapid short release of SMV (4 weeks) vs long sustained release (8 weeks) from acetic anhydride (AA)—and hexanoic anhydride (HA)‐modified ESCMs, respectively.Methods: AA ESCMs loaded with 10 or 50 µg SMV and HA ESCMs loaded with 50 µg SMV were evaluated for biocompatibility and bone formation at 4 and 8 weeks, in 5 mm critical size rat calvarial defects, using histological evaluation and micro‐CT analysis.Results: No severe inflammatory response was noticed around the ESCMs. Less hydrophobic AA membranes showed signs of resorption by week 4 and were almost completely resorbed by week 8 whereas the more hydrophobic HA membranes resorbed slowly, remaining intact over 8 weeks. In micro‐CT analysis, 10 µg SMV‐loaded AA membranes did not show significant bone formation as compared to non‐loaded AA membranes at either evaluation time points. 50 µg SMV‐loaded AA membranes stimulated significantly more bone formation than non‐loaded AA membranes by week 4 (%bone = 31.0 ± 5.9% (AA50) vs 18.5 ± 13.7% (AA0)) but showed no difference at week 8. HA membranes with 50 µg SMV showed significantly more bone formation as compared to corresponding non‐loaded membranes by week 8 (%bone = 61.7 ± 8.9% (HA50) vs 33.9 ± 29.7% (HA0)), though such an effect was not significant at week 4.Conclusion: These results indicate that modified ESCMs may be used to control the release of SMV and promote bone healing in GBR applications.
- 8 April 2021
- Published by Wiley in Journal of Periodontal Research
- Vol. 56 (5) , 877-884
Simvastatin loaded chitosan guided bone regeneration membranes stimulate bone healing
Background and Objective: Electrospun chitosan membranes (ESCM) modified with short‐chain fatty acids have the ability to control the release of simvastatin (SMV), an anti‐cholesterol drug with osteogenic potential, for guided bone regeneration (GBR) applications. This study evaluated in vivo osteogenic effects of rapid short release of SMV (4 weeks) vs long sustained release (8 weeks) from acetic anhydride (AA)—and hexanoic anhydride (HA)‐modified ESCMs, respectively.Methods: AA ESCMs loaded with 10 or 50 µg SMV and HA ESCMs loaded with 50 µg SMV were evaluated for biocompatibility and bone formation at 4 and 8 weeks, in 5 mm critical size rat calvarial defects, using histological evaluation and micro‐CT analysis.Results: No severe inflammatory response was noticed around the ESCMs. Less hydrophobic AA membranes showed signs of resorption by week 4 and were almost completely resorbed by week 8 whereas the more hydrophobic HA membranes resorbed slowly, remaining intact over 8 weeks. In micro‐CT analysis, 10 µg SMV‐loaded AA membranes did not show significant bone formation as compared to non‐loaded AA membranes at either evaluation time points. 50 µg SMV‐loaded AA membranes stimulated significantly more bone formation than non‐loaded AA membranes by week 4 (%bone = 31.0 ± 5.9% (AA50) vs 18.5 ± 13.7% (AA0)) but showed no difference at week 8. HA membranes with 50 µg SMV showed significantly more bone formation as compared to corresponding non‐loaded membranes by week 8 (%bone = 61.7 ± 8.9% (HA50) vs 33.9 ± 29.7% (HA0)), though such an effect was not significant at week 4.Conclusion: These results indicate that modified ESCMs may be used to control the release of SMV and promote bone healing in GBR applications.
- 1 April 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 124, 88-107
Biomaterial-based extracellular vesicle delivery for therapeutic applications
- 1 April 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 124, 88-107
Biomaterial-based extracellular vesicle delivery for therapeutic applications
- 17 May 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 584, 119438
Modified electrospun chitosan membranes for controlled release of simvastatin
- 17 May 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 584, 119438
Modified electrospun chitosan membranes for controlled release of simvastatin
- Top Cited PapersOpen Access
- 31 July 2019
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 10 (3) , 34
Stimuli-Responsive Drug Release from Smart Polymers
Over the past 10 years, stimuli-responsive polymeric biomaterials have emerged as effective systems for the delivery of therapeutics. Persistent with ongoing efforts to minimize adverse effects, stimuli-responsive biomaterials are designed to release in response to either chemical, physical, or biological triggers. The stimuli-responsiveness of smart biomaterials may improve spatiotemporal specificity of release. The material design may be used to tailor smart polymers to release a drug when particular stimuli are present. Smart biomaterials may use internal or external stimuli as triggering mechanisms. Internal stimuli-responsive smart biomaterials include those that respond to specific enzymes or changes in microenvironment pH; external stimuli can consist of electromagnetic, light, or acoustic energy; with some smart biomaterials responding to multiple stimuli. This review looks at current and evolving stimuli-responsive polymeric biomaterials in their proposed applications.
- 31 July 2019
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 10 (3) , 34
Top Cited PapersOpen AccessStimuli-Responsive Drug Release from Smart Polymers
Over the past 10 years, stimuli-responsive polymeric biomaterials have emerged as effective systems for the delivery of therapeutics. Persistent with ongoing efforts to minimize adverse effects, stimuli-responsive biomaterials are designed to release in response to either chemical, physical, or biological triggers. The stimuli-responsiveness of smart biomaterials may improve spatiotemporal specificity of release. The material design may be used to tailor smart polymers to release a drug when particular stimuli are present. Smart biomaterials may use internal or external stimuli as triggering mechanisms. Internal stimuli-responsive smart biomaterials include those that respond to specific enzymes or changes in microenvironment pH; external stimuli can consist of electromagnetic, light, or acoustic energy; with some smart biomaterials responding to multiple stimuli. This review looks at current and evolving stimuli-responsive polymeric biomaterials in their proposed applications.
- 1 June 2016
- Published by IOP Publishing in Biomedical Materials
- Vol. 11 (3) , 035017
Injectable osteogenic and angiogenic nanocomposite hydrogels for irregular bone defects
Injectable hydrogels with their 3D structure and good moldability serve as excellent scaffolding material for regenerating irregular non load-bearing bone defects. Most of the bone defects do not heal completely due to the lack of vasculature required for the transport of nutrients and oxygen to the regenerating tissues. To enhance vasculature, we developed an injectable hydrogel system made of chitin and poly (butylene succinate) (PBSu) loaded with 250 ± 20 nm sized fibrin nanoparticles (FNPs) and magnesium-doped bioglass (MBG). FNPs were expected to enhance vascularisation and MBG was expected to help induce early osteogenesis. Composite hydrogels were analysed using Fourier transform infra-red spectroscopy, scanning electron microscopy (SEM), energy dispersive x-ray spectroscopy, and rheology. Hydrogels with MBG showed a slightly rougher morphology upon SEM analysis. Composites containing 5% MBG and 2% FNPs showed good rheological properties, injectability, temperature stability, biomineralization and protein adsorption. Human umbilical vein endothelial cells (HUVECs) and rabbit-adipose derived mesenchymal stem cells (rASCs) were used for cyto-compatibility studies. Composite gels with 2% FNPs and 2% MBG (composite 1) were considered to be non-toxic to both the cells and were taken for further in vitro studies. Aortic ring assay was carried out to study the angiogenic potential of the hydrogels. The aorta placed with composite hydrogels showed enhanced sprouting of blood vessels. rASCs too showed good spreading on the composite hydrogels. Hydrogels containing MBG showed early initiation of differentiation and higher expression of alkaline phosphatase and osteocalcin confirming the osteoinductive property of MBG. These studies indicate that this composite hydrogel can be used for regenerating irregular bone defects.
- 1 June 2016
- Published by IOP Publishing in Biomedical Materials
- Vol. 11 (3) , 035017
Injectable osteogenic and angiogenic nanocomposite hydrogels for irregular bone defects
Injectable hydrogels with their 3D structure and good moldability serve as excellent scaffolding material for regenerating irregular non load-bearing bone defects. Most of the bone defects do not heal completely due to the lack of vasculature required for the transport of nutrients and oxygen to the regenerating tissues. To enhance vasculature, we developed an injectable hydrogel system made of chitin and poly (butylene succinate) (PBSu) loaded with 250 ± 20 nm sized fibrin nanoparticles (FNPs) and magnesium-doped bioglass (MBG). FNPs were expected to enhance vascularisation and MBG was expected to help induce early osteogenesis. Composite hydrogels were analysed using Fourier transform infra-red spectroscopy, scanning electron microscopy (SEM), energy dispersive x-ray spectroscopy, and rheology. Hydrogels with MBG showed a slightly rougher morphology upon SEM analysis. Composites containing 5% MBG and 2% FNPs showed good rheological properties, injectability, temperature stability, biomineralization and protein adsorption. Human umbilical vein endothelial cells (HUVECs) and rabbit-adipose derived mesenchymal stem cells (rASCs) were used for cyto-compatibility studies. Composite gels with 2% FNPs and 2% MBG (composite 1) were considered to be non-toxic to both the cells and were taken for further in vitro studies. Aortic ring assay was carried out to study the angiogenic potential of the hydrogels. The aorta placed with composite hydrogels showed enhanced sprouting of blood vessels. rASCs too showed good spreading on the composite hydrogels. Hydrogels containing MBG showed early initiation of differentiation and higher expression of alkaline phosphatase and osteocalcin confirming the osteoinductive property of MBG. These studies indicate that this composite hydrogel can be used for regenerating irregular bone defects.
- 1 January 2016
- Published by Elsevier in Carbohydrate Polymers
- Vol. 136, 609-617
Colloidal chitin nanogels: A plethora of applications under one shell
- 1 January 2016
- Published by Elsevier in Carbohydrate Polymers
- Vol. 136, 609-617
Colloidal chitin nanogels: A plethora of applications under one shell
- 1 November 2015
- Published by Elsevier in European Polymer Journal
- Vol. 72, 543-565
An overview of injectable polymeric hydrogels for tissue engineering
- 1 November 2015
- Published by Elsevier in European Polymer Journal
- Vol. 72, 543-565
An overview of injectable polymeric hydrogels for tissue engineering
- Open Access
- 25 August 2015
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 6 (3) , 849-862
Injectable Amorphous Chitin-Agarose Composite Hydrogels for Biomedical Applications
Injectable hydrogels are gaining popularity as tissue engineering constructs because of their ease of handling and minimal invasive delivery. Making hydrogels from natural polymers helps to overcome biocompatibility issues. Here, we have developed an Amorphous Chitin (ACh)-Agarose (Agr) composite hydrogel using a simpletechnique. Rheological studies, such as viscoelastic behavior (elastic modulus, viscous modulus, yield stress, and consistency), inversion test, and injectability test, were carried out for different ACh-Agr concentrations. The composite gel, having a concentration of 1.5% ACh and 0.25% Agr, showed good elastic modulus (17.3 kPa), yield stress (3.8 kPa), no flow under gravity, injectability, and temperature stability within the physiological range. Based on these studies, the optimum concentration for injectability was found to be 1.5% ACh and 0.25% Agr. This optimized concentration was used for further studies and characterized using FT-IR and SEM. FT-IR studies confirmed the presence of ACh and Agr in the composite gel. SEM results showed that the lyophilized composite gel had good porosity and mesh like networks. The cytocompatibility of the composite gel was studied using human mesenchymal stem cells (hMSCs). The composite gels showed good cell viability.These results indicated that this injectable composite gel can be used for biomedical applications.
- 25 August 2015
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 6 (3) , 849-862
Open AccessInjectable Amorphous Chitin-Agarose Composite Hydrogels for Biomedical Applications
Injectable hydrogels are gaining popularity as tissue engineering constructs because of their ease of handling and minimal invasive delivery. Making hydrogels from natural polymers helps to overcome biocompatibility issues. Here, we have developed an Amorphous Chitin (ACh)-Agarose (Agr) composite hydrogel using a simpletechnique. Rheological studies, such as viscoelastic behavior (elastic modulus, viscous modulus, yield stress, and consistency), inversion test, and injectability test, were carried out for different ACh-Agr concentrations. The composite gel, having a concentration of 1.5% ACh and 0.25% Agr, showed good elastic modulus (17.3 kPa), yield stress (3.8 kPa), no flow under gravity, injectability, and temperature stability within the physiological range. Based on these studies, the optimum concentration for injectability was found to be 1.5% ACh and 0.25% Agr. This optimized concentration was used for further studies and characterized using FT-IR and SEM. FT-IR studies confirmed the presence of ACh and Agr in the composite gel. SEM results showed that the lyophilized composite gel had good porosity and mesh like networks. The cytocompatibility of the composite gel was studied using human mesenchymal stem cells (hMSCs). The composite gels showed good cell viability.These results indicated that this injectable composite gel can be used for biomedical applications.